ROBERT STRAYHAN: Open Payments
NPI 1023178043 · CHEYENNE, WY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$538 in 31 payments from 8 companies in 2025. Trend: 2023 $1,718 · 2024 $1,866 · 2025 $538
Food & beverage: $538
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $378 |
| Janssen Pharmaceuticals, Inc | 2 | $32 |
| Lundbeck LLC | 2 | $31 |
| Supernus Pharmaceuticals, Inc. | 1 | $28 |
| Neurocrine BioSciences, Inc. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $18 |
| Alkermes, Inc. | 1 | $14 |
Products named: VRAYLAR, INVEGA SUSTENNA, REXULTI, Qelbree, INGREZZA, ABILIFY MAINTENA, CAPLYTA, ARISTADA.
Industry payments across WY — which companies pay providers there.
